Financial

News

Moderna will cut $1.1bn off its annual R&D spend

Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr

News

BIA sends message to UK chancellor on R&D tax credits

The BioIndustry Association (BIA) has asked new UK Chancellor Rachel Reeves for a nuanced approach to R&D tax credits in the upcoming budget, saying that the life sciences should not be

News

BioMarin's change in direction claims more jobs

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Bayer CEO says recovery on track as key drug products shine

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.

News

Anne Wojcicki, CEO and co-founder of 23andMe

23andMe board rebuffs CEO plan to take the firm private

A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.

Moderna will cut $1.1bn off its annual R&D spend

BIA sends message to UK chancellor on R&D tax credits

BioMarin's change in direction claims more jobs

Lilly says tirzepatide supply issues are resolving

Bayer CEO says recovery on track as key drug products shine

23andMe board rebuffs CEO plan to take the firm private

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Financial

Editor's Picks